Veracyte

VCYT

Market cap $4.72B

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will b.

Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Chief Accounting Officer Jonathan Wygant sold 24,000 shares on May 22, 2026, generating a transaction value of ~$1.09 million at an average price around $45.40 per share. This transaction reduced direct holdings by 34.57%, leaving 45,434 shares directly owned post-sale.

VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a debt-free balance sheet.

A director of Veracyte reported selling 3,729 shares for a transaction value of approximately $197K on June 18, 2026. This disposition represented roughly 20% of Karin Eastham's direct common stock holdings, reducing direct ownership to 15,097 shares.

Veracyte opened its doors with a simple theory: Not all cancer patients need surgery or chemotherapy. Now, Veracyte stock is on a run.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.